- Biopharma News
Abzena and BioXpress Therapeutics partner to provide global biosimilar support27 Jul 2021
The combined capabilities will offer flexibility and innovation from small-scale biosimilar development through to large-scale manufacturing
Abzena and BioXpress Therapeutics have formed a partnership to support biosimilar development for third-party customers.
The partnership creates an integrated solution between two service providers with expertise in biosimilar development and good manufacturing practice (GMP), allowing for a simplified drug development timelines for the biosimilars market.
Furthermore, the combined expertise will provide a flexible and innovative approach from small-scale biosimilar development through to large-scale manufacturing.
Biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.
According to Abzena's CEO, Jonathan Goldman, the combined services will provide customers with a "de-risked approach" to biosimilar development, through to clinical development and ultimately to the market.”
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation